Wells Fargo analyst Derek Archila has upgraded Q32 Bio (NASDAQ: QTTB) from Equal-Weight to Overweight and announced a price target of $66. This bullish stance follows a separate endorsement from Oppenheimer, which maintained its Outperform rating and raised its price target to $40. The revised targets from both firms reflect increased confidence in the biotechnology company's prospects and its potential to deliver above-market returns.

Rating and Target Details

The consensus among analysts is shifting positively for Q32 Bio. Wells Fargo's upgrade to Overweight and the establishment of a $66 price target mark a significant shift from its previous Equal-Weight rating. Simultaneously, Oppenheimer's Jay Olson doubled his price target from $20 to $40 while retaining an Outperform rating.

The Outperform and Overweight ratings suggest that Q32 Bio is expected to outperform the broader market in the near term. The significant disparity in the new price targets highlights varying degrees of optimism among analysts regarding the company's future performance.

Q32 Bio Inc. announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata. The data demonstrated a mean percent reduction in SALT score from baseline of 35.3% in the prespecified modified intent-to-treat (mITT) analysis. The company intends to advance the drug into a registration-directed program in the first half of 2027.

Key Efficacy Results

The trial met its primary endpoint and showed clinically meaningful efficacy across various measures. The results indicated that 40.0% of patients in the mITT analysis and 30.3% of patients in the intent-to-treat (ITT) analysis achieved a SALT-20 response at Week 36. SALT-20 is defined as 80% of scalp hair coverage.

Safety and Tolerability

Bempikibart exhibited a generally well-tolerated safety profile consistent with prior studies, with no new safety signals observed. There were no serious adverse events or Grade 3 or higher adverse events related to treatment. The most common treatment-emergent adverse event was injection site reaction (ISR), occurring in 36.3% of patients, though these were primarily singular events with an incidence of 4% across all dose administrations. All ISRs were mild and resolved without intervention.

Trial Design and Next Steps

Part B of the SIGNAL-AA program was an open-label trial evaluating 33 patients with severe or very severe alopecia areata. The dosing regimen included an initial loading phase of 200mg weekly for four doses, followed by 200mg every other week for 32 weeks. The company plans to share full results from Part B at a future medical meeting. Q32 Bio will host a conference call and webcast today, July 13, 2026, at 8:00 a.m. ET to discuss the findings.